Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014


#208121

320pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2014, provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 12
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 19
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 25
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 29
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 30
Johnson & Johnson 30
Boehringer Ingelheim GmbH 31
Amgen Inc. 32
AstraZeneca PLC 33
Eli Lilly and Company 34
GlaxoSmithKline plc 35
Genentech, Inc. 36
Bavarian Nordic A/S 37
Isis Pharmaceuticals, Inc. 38
Daiichi Sankyo Company, Limited 39
Oxford BioMedica plc 40
Plexxikon Inc. 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
Aphios Corporation 44
Astellas Pharma Inc. 45
Orion Corp 46
Astex Pharmaceuticals, Inc. 47
Santaris Pharma A/S 48
A. Menarini Industrie Farmaceutiche Riunite Srl 49
Bayer AG 50
Harbor Therapeutics, Inc. 51
Celldex Therapeutics, Inc. 52
ValiRx Plc 53
AEterna Zentaris Inc. 54
Arrowhead Research Corporation 55
Northwest Biotherapeutics, Inc. 56
Medivation, Inc. 57
Oncogenex Pharmaceuticals, Inc. 58
AnGes MG, Inc. 59
e-Therapeutics plc 60
Hybrigenics S.A. 61
Fujifilm Corporation 62
CureVac GmbH 63
Tokai Pharmaceuticals, Inc. 64
Arno Therapeutics, Inc. 65
Orphagen Pharmaceuticals, Inc. 66
Enceladus Pharmaceuticals BV 67
NewLink Genetics Corporation 68
Kinex Pharmaceuticals, LLC 69
Adamis Pharmaceuticals Corporation 70
CureTech Ltd. 71
Viamet Pharmaceuticals, Inc. 72
Incuron, LLC 73
Ausio Pharmaceuticals, LLC 74
Errant Gene Therapeutics, LLC 75
Miami VA Healthcare System 76
Tesaro, Inc. 77
Panacela Labs, Inc. 78
Io Therapeutics, Inc. 79
Antoxis Limited 80
Armour Therapeutics Inc. 81
Medvio Eurasia 82
Biscayne Pharmaceuticals, Inc. 83
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 84
Assessment by Monotherapy Products 84
Assessment by Target 85
Assessment by Mechanism of Action 89
Assessment by Route of Administration 93
Assessment by Molecule Type 95
Drug Profiles 98
abiraterone acetate - Drug Profile 98
enzalutamide - Drug Profile 101
DCVax-Prostate - Drug Profile 104
radium Ra 223 dichloride - Drug Profile 105
JNJ-56021927 - Drug Profile 108
ITK-1 - Drug Profile 110
zoptarelin doxorubicin - Drug Profile 112
sabarubicin - Drug Profile 114
alisertib - Drug Profile 116
ISIS-EIF4ERx - Drug Profile 119
apatorsen - Drug Profile 121
AT-13387 - Drug Profile 123
HE-3235 - Drug Profile 126
TroVax - Drug Profile 128
ramucirumab - Drug Profile 131
galeterone - Drug Profile 136
mepacrine - Drug Profile 138
radium Ra 223 dichloride - Drug Profile 140
pidilizumab - Drug Profile 143
CV-9103 - Drug Profile 145
exatecan mesylate - Drug Profile 147
PLX-3397 - Drug Profile 149
buparlisib hydrochloride - Drug Profile 151
afatinib - Drug Profile 154
Cancer Inhibitor Macrobeads - Drug Profile 157
inecalcitol - Drug Profile 158
KX-01 - Drug Profile 160
ODM-201 - Drug Profile 162
IRX-4204 - Drug Profile 164
VT-464 - Drug Profile 166
KRM-20 - Drug Profile 167
rilotumumab - Drug Profile 168
GEN-0101 - Drug Profile 170
Autologous Dendritic Cell Vaccine - Drug Profile 172
MVA-BN-PRO - Drug Profile 173
HyperAcute for Prostate Cancer - Drug Profile 174
ipatasertib - Drug Profile 175
VT-464 - Drug Profile 177
onapristone ER - Drug Profile 178
niraparib - Drug Profile 180
varlilumab - Drug Profile 182
solitomab - Drug Profile 183
AUS-131 - Drug Profile 185
BMTP-11 - Drug Profile 187
VAL-201 - Drug Profile 188
MT-112 - Drug Profile 189
EZN-4176 - Drug Profile 191
LFA-102 - Drug Profile 193
G-47 Delta - Drug Profile 195
TeloB-VAX - Drug Profile 196
pasireotide LAR - Drug Profile 197
AZD-3965 - Drug Profile 199
AM-0010 - Drug Profile 200
AZD-8186 - Drug Profile 201
GSK-2849330 - Drug Profile 202
HE-3235 - Drug Profile 203
AMPI-109 - Drug Profile 205
ETS-2123 - Drug Profile 206
JW-1521 - Drug Profile 207
APH-0701 - Drug Profile 208
Arkil - Drug Profile 209
AT-001 - Drug Profile 210
Growth Hormone - Releasing Hormone Antagonists - Drug Profile 211
BAY-1024767 - Drug Profile 212
Small Molecule to Inhibit 17-Beta-HSD for Prostate Cancer - Drug Profile 213
GPA-500 - Drug Profile 214
MVI-118 - Drug Profile 215
dexamethasone acetate liposomal - Drug Profile 216
EPI-001 - Drug Profile 217
MIA-602 - Drug Profile 218
Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer - Drug Profile 219
AO-1530 - Drug Profile 220
SU-1361 - Drug Profile 221
Steroidogenic Factor-1 Antagonists - Drug Profile 222
Small Molecule to Inhibit AKR1C3 for Oncology - Drug Profile 223
Small Molecule to Inhibit Androgen Receptor for Hormone Refractory Prostate Cancer - Drug Profile 224
DendriVax - Drug Profile 225
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 226
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 299
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 303
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 304
Featured News & Press Releases 304

Appendix 314
Methodology 314
Coverage 314
Secondary Research 314
Primary Research 314
Expert Panel Validation 314
Contact Us 315
Disclaimer 315

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 20
Number of Products under Development by Companies, H1 2014 (Contd..1) 21
Number of Products under Development by Companies, H1 2014 (Contd..2) 22
Number of Products under Development by Companies, H1 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 26
Comparative Analysis by Clinical Stage Development, H1 2014 27
Comparative Analysis by Early Stage Development, H1 2014 28
Comparative Analysis by Unknown Stage Development, H1 2014 29
Products under Development by Companies, H1 2014 30
Products under Development by Companies, H1 2014 (Contd..1) 31
Products under Development by Companies, H1 2014 (Contd..2) 32
Products under Development by Companies, H1 2014 (Contd..3) 33
Products under Investigation by Universities/Institutes, H1 2014 34
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H1 2014 35
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 36
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H1 2014 37
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2014 38
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2014 39
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 40
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2014 41
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S , H1 2014 42
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 43
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 44
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oxford BioMedica plc, H1 2014 45
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Plexxikon Inc., H1 2014 46
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 47
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2014 48
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H1 2014 49
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2014 50
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Corp, H1 2014 51
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 52
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Santaris Pharma A/S, H1 2014 53
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 54
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H1 2014 55
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H1 2014 56
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2014 57
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ValiRx Plc, H1 2014 58
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AEterna Zentaris Inc., H1 2014 59
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Research Corporation, H1 2014 60
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 61
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2014 62
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 63
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H1 2014 64
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by e-Therapeutics plc, H1 2014 65
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H1 2014 66
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H1 2014 67
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H1 2014 68
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H1 2014 69
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 71
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 72
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 74
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 75
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureTech Ltd., H1 2014 76
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viamet Pharmaceuticals, Inc., H1 2014 77
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Incuron, LLC, H1 2014 78
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ausio Pharmaceuticals, LLC, H1 2014 79
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H1 2014 80
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Miami VA Healthcare System, H1 2014 81
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro, Inc., H1 2014 82
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Panacela Labs, Inc., H1 2014 83
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H1 2014 84
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Antoxis Limited, H1 2014 85
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2014 86
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medvio Eurasia, H1 2014 87
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2014 88
Assessment by Monotherapy Products, H1 2014 89
Number of Products by Stage and Target, H1 2014 92
Number of Products by Stage and Mechanism of Action, H1 2014 96
Number of Products by Stage and Route of Administration, H1 2014 99
Number of Products by Stage and Molecule Type, H1 2014 102
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2014 231
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2014 304
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H1 2014 305
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H1 2014 306
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H1 2014 307
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2014 308

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 19
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 27
Comparative Analysis by Early Stage Products, H1 2014 28
Assessment by Monotherapy Products, H1 2014 89
Number of Products by Top 10 Target, H1 2014 90
Number of Products by Stage and Top 10 Target, H1 2014 91
Number of Products by Top 10 Mechanism of Action, H1 2014 94
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 95
Number of Products by Top 10 Route of Administration, H1 2014 98
Number of Products by Stage and Top 10 Route of Administration, H1 2014 99
Number of Products by Top 10 Molecule Type, H1 2014 100
Number of Products by Stage and Top 10 Molecule Type, H1 2014 101